Status:
TERMINATED
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
Lead Sponsor:
University of Nebraska
Conditions:
Type 2 Diabetes
End Stage Renal Disease
Eligibility:
All Genders
19-70 years
Phase:
PHASE4
Brief Summary
This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.
Detailed Description
New-onset diabetes after transplantation (NODAT) is a complication of solid organ transplantation. In the University of Nebraska Medical Center (UNMC) Kidney-Pancreas Transplant Clinic, the frequency ...
Eligibility Criteria
Inclusion
- Recipient of a kidney transplant at UNMC, including cadaveric or living donor transplant.
Exclusion
- A previous diagnosis of diabetes or previous criteria for diabetes, according to the American Diabetes Association, not previously recognized as diabetes.
- Simultaneous transplant of another solid organ, such liver or heart.
- Patient unable to take oral medication.
- Patient unable to give informed consent.
- Hypersensitivity to sitagliptin.
Key Trial Info
Start Date :
July 6 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00936663
Start Date
July 6 2009
End Date
June 1 2010
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198